Date: 2013-01-23
Type of information: Initiation of the trial
phase: 1b
Announcement: initiation of the trial
Company: BMS (USA - NY)
Product: urelumab (BMS-663513) and rituximab
Action
mechanism: monoclonal antibody. Urelumab (BMS-663513) is an agonist of the CD137 co-stimulatory receptor. This monoclonal antibody specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. CD137 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors and is expressed by activated T- and B-lymphocytes and monocytes. Rituximab is a therapeutic monoclonal antibody that binds to the CD20 antigen on the surface of normal and malignant B-cells. It then recruits the body’s natural defenses to attack and kill the marked B-cells.
Disease: B-cell non-Hodgkins lymphoma
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: The phase 1b, open-label, multicenter study evaluates urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies. The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of urelumab in combination with rituximab in patients with B-cell non-Hodgkins lymphoma. (NCT01775631)
Latest news:
